Under the joint venture agreement, pending European Union regulatory approval, DuPont and DSM will each share a 50% interest and address the market for surgical sealants, adhesion barriers and tissue adhesives.

Actamax Surgical Materials will build a comprehensive biomedical product portfolio based on several patent-protected biodegradable hydrogel technologies and the early technology development was completed using DuPont materials science and biotechnology capabilities.

Actamax Surgical Materials is a strategic component of the DuPont Applied BioSciences business, which integrates biotechnology with other sciences to create products that can transform large, addressable markets.

The joint venture will focus on the clinical validation of the products and technology, and commercialisation will include manufacture and sale of proprietary products as well as the establishment of joint development relationships with medical device companies.

DuPont Applied BioSciences vice president John Ranieri said that their platform of technologies will offer physicians and patients improved outcomes of surgery that will prevent post-operative complications while reducing health care costs.

“Actamax will deliver a number of products that can be optimized for different surgical situations and clinical needs. The success DSM has had in the biomedical materials market makes them an ideal strategic partner for us to commercialise our technology portfolio,” Ranieri said.